Corebridge Financial Inc. Has $498,000 Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Corebridge Financial Inc. trimmed its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 7.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,196 shares of the medical equipment provider’s stock after selling 1,490 shares during the period. Corebridge Financial Inc.’s holdings in BioLife Solutions were worth $498,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of BLFS. Steward Partners Investment Advisory LLC bought a new position in BioLife Solutions during the fourth quarter worth about $26,000. 1620 Investment Advisors Inc. raised its holdings in shares of BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 675 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 950 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of BioLife Solutions during the 4th quarter worth approximately $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in BioLife Solutions in the 4th quarter valued at $201,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BLFS has been the subject of several recent analyst reports. KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Northland Securities increased their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reissued a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. StockNews.com raised shares of BioLife Solutions from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, HC Wainwright lifted their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $31.17.

Insiders Place Their Bets

In related news, CMO Todd Berard sold 1,577 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,425.00. Following the completion of the sale, the chief marketing officer now directly owns 104,961 shares of the company’s stock, valued at $2,624,025. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Sarah Aebersold sold 1,091 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00. Following the completion of the transaction, the insider now owns 58,816 shares in the company, valued at $1,470,400. This represents a 1.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,092 shares of company stock valued at $1,635,609. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Stock Down 5.9 %

Shares of NASDAQ BLFS opened at $20.64 on Wednesday. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The firm’s 50-day simple moving average is $25.43 and its 200 day simple moving average is $25.41. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a market cap of $970.08 million, a price-to-earnings ratio of -19.47 and a beta of 1.93.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same period in the prior year, the business earned ($0.21) earnings per share. On average, research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.